These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

218 related items for PubMed ID: 15317466

  • 21. Design, synthesis, and evaluation of non-steroidal farnesoid X receptor (FXR) antagonist.
    Kainuma M, Makishima M, Hashimoto Y, Miyachi H.
    Bioorg Med Chem; 2007 Apr 01; 15(7):2587-600. PubMed ID: 17292610
    [Abstract] [Full Text] [Related]

  • 22. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.
    Evans MJ, Mahaney PE, Borges-Marcucci L, Lai K, Wang S, Krueger JA, Gardell SJ, Huard C, Martinez R, Vlasuk GP, Harnish DC.
    Am J Physiol Gastrointest Liver Physiol; 2009 Mar 01; 296(3):G543-52. PubMed ID: 19136377
    [Abstract] [Full Text] [Related]

  • 23. Diphenylmethane skeleton as a multi-template for nuclear receptor ligands: preparation of FXR and PPAR ligands.
    Kainuma M, Kasuga J, Hosoda S, Wakabayashi K, Tanatani A, Nagasawa K, Miyachi H, Makishima M, Hashimoto Y.
    Bioorg Med Chem Lett; 2006 Jun 15; 16(12):3213-8. PubMed ID: 16617018
    [Abstract] [Full Text] [Related]

  • 24. Bile acids reduce SR-BI expression in hepatocytes by a pathway involving FXR/RXR, SHP, and LRH-1.
    Malerød L, Sporstøl M, Juvet LK, Mousavi SA, Gjøen T, Berg T, Roos N, Eskild W.
    Biochem Biophys Res Commun; 2005 Nov 04; 336(4):1096-105. PubMed ID: 16168958
    [Abstract] [Full Text] [Related]

  • 25. Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
    Katona BW, Cummins CL, Ferguson AD, Li T, Schmidt DR, Mangelsdorf DJ, Covey DF.
    J Med Chem; 2007 Nov 29; 50(24):6048-58. PubMed ID: 17963371
    [Abstract] [Full Text] [Related]

  • 26. The Farnesoid X receptor: a molecular link between bile acid and lipid and glucose metabolism.
    Claudel T, Staels B, Kuipers F.
    Arterioscler Thromb Vasc Biol; 2005 Oct 29; 25(10):2020-30. PubMed ID: 16037564
    [Abstract] [Full Text] [Related]

  • 27. FXR: a promising target for the metabolic syndrome?
    Cariou B, Staels B.
    Trends Pharmacol Sci; 2007 May 29; 28(5):236-43. PubMed ID: 17412431
    [Abstract] [Full Text] [Related]

  • 28. FXR: a metabolic regulator and cell protector.
    Wang YD, Chen WD, Moore DD, Huang W.
    Cell Res; 2008 Nov 29; 18(11):1087-95. PubMed ID: 18825165
    [Abstract] [Full Text] [Related]

  • 29. Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus.
    Capello A, Moons LM, Van de Winkel A, Siersema PD, van Dekken H, Kuipers EJ, Kusters JG.
    Am J Gastroenterol; 2008 Jun 29; 103(6):1510-6. PubMed ID: 18510604
    [Abstract] [Full Text] [Related]

  • 30. Bile acid signaling through FXR induces intracellular adhesion molecule-1 expression in mouse liver and human hepatocytes.
    Qin P, Borges-Marcucci LA, Evans MJ, Harnish DC.
    Am J Physiol Gastrointest Liver Physiol; 2005 Aug 29; 289(2):G267-73. PubMed ID: 15817812
    [Abstract] [Full Text] [Related]

  • 31. In vivo imaging of farnesoid X receptor activity reveals the ileum as the primary bile acid signaling tissue.
    Houten SM, Volle DH, Cummins CL, Mangelsdorf DJ, Auwerx J.
    Mol Endocrinol; 2007 Jun 29; 21(6):1312-23. PubMed ID: 17426284
    [Abstract] [Full Text] [Related]

  • 32. Analysis of bile acid-induced regulation of FXR target genes in human liver slices.
    Jung D, Elferink MG, Stellaard F, Groothuis GM.
    Liver Int; 2007 Feb 29; 27(1):137-44. PubMed ID: 17241392
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. New targets in and potential treatments for cholesterol gallstone disease.
    Doggrell SA.
    Curr Opin Investig Drugs; 2006 Apr 29; 7(4):344-8. PubMed ID: 16625821
    [Abstract] [Full Text] [Related]

  • 35. Extending SAR of bile acids as FXR ligands: discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine.
    Gioiello A, Macchiarulo A, Carotti A, Filipponi P, Costantino G, Rizzo G, Adorini L, Pellicciari R.
    Bioorg Med Chem; 2011 Apr 15; 19(8):2650-8. PubMed ID: 21459580
    [Abstract] [Full Text] [Related]

  • 36. Farnesoid X receptor modulates renal lipid metabolism, fibrosis, and diabetic nephropathy.
    Jiang T, Wang XX, Scherzer P, Wilson P, Tallman J, Takahashi H, Li J, Iwahashi M, Sutherland E, Arend L, Levi M.
    Diabetes; 2007 Oct 15; 56(10):2485-93. PubMed ID: 17660268
    [Abstract] [Full Text] [Related]

  • 37. Hologram quantitative structure-activity relationships for a series of farnesoid X receptor activators.
    Honorio KM, Garratt RC, Andricopulo AD.
    Bioorg Med Chem Lett; 2005 Jun 15; 15(12):3119-25. PubMed ID: 15893927
    [Abstract] [Full Text] [Related]

  • 38. The farnesoid X receptor is expressed in breast cancer and regulates apoptosis and aromatase expression.
    Swales KE, Korbonits M, Carpenter R, Walsh DT, Warner TD, Bishop-Bailey D.
    Cancer Res; 2006 Oct 15; 66(20):10120-6. PubMed ID: 17047076
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.